Bought
Maintained
Sold
Other funds holding AZN
PI
SCCM
EIP
UBS's AZN Position: Q3 2014 in Review
UBS reduced its AstraZeneca (AZN) stake by 2.7% in Q3 2014, selling an estimated $3.49M and leaving 1,725,695 shares worth $123M. The position accounts for 0.09% of the portfolio, ranked #231.
UBS first reported a position in AZN in Q2 2013 and has held it in 6 quarters since. The position peaked at $295M in Q3 2013. 401 funds tracked by Wall St. Rank hold AZN as of Q3 2014.
- UBS held 1,725,695 shares of AstraZeneca worth $123M as of Q3 2014.
- UBS sold 47,642 AstraZeneca shares in Q3 2014, an estimated $3.49M.
- AstraZeneca made up 0.09% of UBS's portfolio in Q3 2014, its #231 holding.
- UBS first reported a position in AstraZeneca in Q2 2013 and has held it in 6 quarters since.
- UBS's AstraZeneca position peaked at $295M in Q3 2013.
- 401 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.
Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.